Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.72 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.72 |
| ▸ | MEN1 | O00255 | 6/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.54 |
| ▸ | DRD3 | P35462 | 4/20 | 0.52 |
| ▸ | DRD4 | P21917 | 3/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4725109 | 0.77 | GRM2 (0.77) | DRD2GRM2MEN1KMT2ADRD3 | |
| SCHEMBL4725468 | 0.76 | GRM2 (0.77) | DRD2GRM2DRD3DRD4 | |
| SCHEMBL4726289 | 0.74 | GRM2 (0.72) | DRD2GRM2MEN1KMT2ADRD3 | |
| SCHEMBL4925251 | 0.73 | GRM2 (0.71) | DRD2GRM2MEN1KMT2ADRD3 | |
| SCHEMBL4725327 | 0.73 | GRM2 (0.73) | DRD2GRM2DRD3DRD4 | |
| Hydrochloric Acid SCHEMBL4777820 | 0.72 | GRM2 (0.72) | DRD2GRM2DRD3DRD4 | |
| SCHEMBL4747037 | 0.71 | DRD2 (0.76) | DRD2GRM2MEN1KMT2ADRD4 | |
| SCHEMBL13777216 | 0.70 | GRM2 (0.70) | DRD2GRM2DRD3DRD4 | |
| SCHEMBL4728476 | 0.70 | GRM2 (0.73) | DRD2GRM2MEN1KMT2ADRD3 | |
| SCHEMBL4154812 | 0.70 | GRM2 (0.69) | DRD2GRM2MEN1KMT2ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | EFREMOV IVAN | 2008-11-13 | — | — | US | disclosed |
| WO-2008012623-A1 | BENZIMIDAZOLYL COMPOUNDS AS POTENTIATORS OF MGLUR2 SUBTYPE OF GLUTAMATE RECEPTOR | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | PAICS, TMBIM6, ABCG2 | DRD2 2308/4885GRM2 4477/4885MEN1 847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.